Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Revenue: 2018-2023

Historic Revenue for Denali Therapeutics (DNLI) over the last 6 years, with Dec 2023 value amounting to $330.5 million.

  • Denali Therapeutics' Revenue fell 64.40% to $1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $340.8 million, marking a year-over-year increase of 207.89%. This contributed to the annual value of $330.5 million for FY2023, which is 204.74% up from last year.
  • Latest data reveals that Denali Therapeutics reported Revenue of $330.5 million as of FY2023, which was up 204.74% from $108.5 million recorded in FY2022.
  • In the past 5 years, Denali Therapeutics' Revenue registered a high of $335.7 million during FY2020, and its lowest value of $26.7 million during FY2019.
  • For the 3-year period, Denali Therapeutics' Revenue averaged around $162.6 million, with its median value being $108.5 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first spiked by 1,158.19% in 2020, then plummeted by 85.50% in 2021.
  • Yearly analysis of 5 years shows Denali Therapeutics' Revenue stood at $26.7 million in 2019, then surged by 1,158.19% to $335.7 million in 2020, then tumbled by 85.50% to $48.7 million in 2021, then skyrocketed by 122.90% to $108.5 million in 2022, then soared by 204.74% to $330.5 million in 2023.